Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

08. April 2026 07:00 ET | Quelle: Incyclix Bio

Incyclix Bio Raises Additional $5 Million in Series B Financing to Advance Clinical Trial of INX-315 in Patients with CDK4/6 Inhibitor Resistant ER+/HER2- Breast Cancer or CCNE1-Amplified Solid Tumors

RESEARCH TRIANGLE PARK, N.C., April 08, 2026 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for...
07. April 2026 12:13 ET | Quelle: Research and Markets

Purvalanol A (CDK Inhibitor) Market Report 2026: Expanding Molecular Biology and Cancer Research Fuelling Market Growth

Dublin, April 07, 2026 (GLOBE NEWSWIRE) -- The "Purvalanol A (CDK Inhibitor) Market Report 2026" has been added to ResearchAndMarkets.com's offering. The Purvalanol A (CDK Inhibitor) market has...
02. Dezember 2025 04:10 ET | Quelle: Research and Markets

Abemaciclib Research Report 2025: Eli Lilly and Company Dominates the $1.6 Billion Market - Long-term Forecasts to 2029 and 2034

Dublin, Dec. 02, 2025 (GLOBE NEWSWIRE) -- The "Abemaciclib Market Report 2025" report has been added to ResearchAndMarkets.com's offering.The abemaciclib market size has grown rapidly in recent...
21. Juni 2023 13:00 ET | Quelle: DelveInsight Business Research LLP

Cyclin-Dependent Kinase Inhibitor Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 50+ Leading Players Wheeling the Therapeutics Landscape

New York, USA, June 21, 2023 (GLOBE NEWSWIRE) -- Cyclin-Dependent Kinase Inhibitor Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 50+ Leading Players...